The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score
Open accessAbstract
OBJECTIVE: To develop and validate a novel, machine learning–derived model to predict the risk of heart failure (HF) among patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: Using data from 8,756 patients free at baseline of HF, with <10% missing data, and enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, we used random survival forest (RSF) methods, a nonparametric decision tree machine learning approach, to identify predictors of incident HF. The RSF model was externally validated in a cohort of individuals with T2DM using the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). RESULTS: Over a median follow-up of 4.9 years, 319 patients (3.6%) developed incident HF. The RSF models demonstrated better discrimination than the best performing Cox-based method (C-index 0.77 [95% CI 0.75–0.80] vs. 0.73 [0.70–0.76] respectively) and had acceptable calibration (Hosmer-Lemeshow statistic χ2 = 9.63, P = 0.29) in the internal validation data set. From the identified predictors, an integer-based risk score for 5-year HF incidence was created: the WATCH-DM (Weight [BMI], Age, hyperTension, Creatinine, HDL-C, Diabetes control [fasting plasma glucose], QRS Duration, MI, and CABG) risk score. Each 1-unit increment in the risk score was associated with a 24% higher relative risk of HF within 5 years. The cumulative 5-year incidence of HF increased in a graded fashion from 1.1% in quintile 1 (WATCH-DM score ≤7) to 17.4% in quintile 5 (WATCH-DM score ≥14). In the external validation cohort, the RSF-based risk prediction model and the WATCH-DM risk score performed well with good discrimination (C-index = 0.74 and 0.70, respectively), acceptable calibration (P ≥0.20 for both), and broad risk stratification (5-year HF risk range from 2.5 to 18.7% across quintiles 1–5). CONCLUSIONS: We developed and validated a novel, machine learning–derived risk score that integrates readily available clinical, laboratory, and electrocardiographic variables to predict the risk of HF among outpatients with T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
MissForest—Non-parametric missing value imputation for mixed-type data
Stekhoven, D. J., & Bühlmann, P. (2012) · Bioinformatics · doi:10.1093/bioinformatics/btr597 · Cited by 6,156
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Self-citationYancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
Self-citationIshwaran, H., Kogalur, U. B., Blackstone, E. H., & Lauer, M. S. (2008) · The Annals of Applied Statistics · doi:10.1214/08-aoas169 · Cited by 2,714
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800256 · Cited by 1,475
Self-citationIshwaran, H., Kogalur, U. B., Blackstone, E. H., & Lauer, M. S. (2008) · Cited by 1,310
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
Buse, J. B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.003 · Cited by 661
Prognostic Models With Competing Risks: Methods and Application to Coronary Risk Prediction
Wolbers, M., Koller, M. T., Witteman, J. C. M., & Steyerberg, E. W. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a39056 · Cited by 625
Risk models and scores for type 2 diabetes: systematic review
Noble, D., Mathur, R., Dent, T., Meads, C., & Greenhalgh, T. (2011) · BMJ · doi:10.1136/bmj.d7163 · Cited by 551
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Cefalu, W. T., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M. L., Morris, P. B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.020 · Cited by 300
Self-citationRandom survival forests for competing risks
Ishwaran, H., Gerds, T. A., Kogalur, U. B., Moore, R. D., Gange, S. J., & Lau, B. M. (2014) · Biostatistics · doi:10.1093/biostatistics/kxu010 · Cited by 297
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes
Everett, B. M., Brooks, M. M., Vlachos, H. E. A., Chaitman, B. R., Frye, R. L., & Bhatt, D. L. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415921 · Cited by 268
Self-citationDisparities in Cardiovascular Mortality Related to Heart Failure in the United States
Glynn, P., Lloyd-Jones, D. M., Feinstein, M. J., Carnethon, M., & Khan, S. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.042 · Cited by 246
McAllister, D. A., Read, S. H., Kerssens, J., Livingstone, S., McGurnaghan, S., Jhund, P., Petrie, J., Sattar, N., Fischbacher, C., Kristensen, S. L., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034986 · Cited by 244
Fitchett, D., Butler, J., van de Borne, P., Zinman, B., Lachin, J. M., Wanner, C., Woerle, H. J., Hantel, S., George, J. T., Johansen, O. E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx511 · Cited by 242
Self-citationDavis, B. R., Kostis, J. B., Simpson, L. M., Black, H. R., Cushman, W. C., Einhorn, P. T., Farber, M. A., Ford, C. E., Levy, D., Massie, B. M., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.762229 · Cited by 204
10-Year Risk Equations for Incident Heart Failure in the General Population
Khan, S. S., Ning, H., Shah, S. J., Yancy, C. W., Carnethon, M., Berry, J. D., Mentz, R. J., O’Brien, E., Correa, A., Suthahar, N., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.057 · Cited by 196
Self-citationMcGuire, D. K., Alexander, J. H., Johansen, O. E., Perkovic, V., Rosenstock, J., Cooper, M. E., Wanner, C., Kahn, S. E., Toto, R. D., Zinman, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038352 · Cited by 164
Self-citationHuang, C.-X., Murugiah, K., Mahajan, S., Li, S.-X., Dhruva, S., Haimovich, J., Wang, Y.-F., Schulz, W. L., Testani, J., Wilson, F., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002703 · Cited by 115
Scirica, B. M., Bhatt, D. L., Braunwald, E., Raz, I., Cavender, M. A., Im, K., Mosenzon, O., Udell, J. A., Hirshberg, B., Pollack, P. S., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3030 · Cited by 104
Einhorn, P. T., Davis, B. R., Massie, B. M., Cushman, W. C., Piller, L. B., Simpson, L. M., Levy, D. A., Nwachuku, C., & Black, H. R. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.10.012 · Cited by 69
Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
Standl, E., Schnell, O., & McGuire, D. K. (2016) · Circulation Research · doi:10.1161/circresaha.116.306924 · Cited by 60
Self-citationGreene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.047 · Cited by 56
Self-citationGurm, H. S., Kooiman, J., Lalonde, T. A., Grines, C. L., Share, D. A., & Seth, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096385 · Cited by 54
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Circulation · doi:10.1161/circulationaha.117.032099 · Cited by 32
Self-citationSEVERE MITRAL STENOSIS AND PULMONARY HYPERTENSION IN PREGNANCY: WHEN TO ACT
Erinne, I., Alam, A., Huang, M. S., Mody, K. P., Ghaly, A., & Iyer, D. B. (2019) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(19)32994-8 · Cited by 14
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationChicco, D., & Jurman, G. (2020) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-020-1023-5 · Cited by 596
Cardiovascular risk in diabetes mellitus: Epidemiology, assessment and prevention
Wong, N. D., & Sattar, N. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00877-z · Cited by 495
Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000920 · Cited by 192
Self-citationMachine learning in precision diabetes care and cardiovascular risk prediction
Oikonomou, E. K., & Khera, R. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01985-3 · Cited by 190
Metadata
- Authors
- Segar, M. W., Vaduganathan, M., Patel, K. V., McGuire, D. K., Butler, J., Fonarow, G. C., Basit, M., Kannan, V., Grodin, J. L., Everett, B., Willett, D., Berry, J., & Pandey, A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-09-13
- Volume
- 42
- Issue
- 12
- Pages
- 2298-2306
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2972732442
- Cited by
- 299
- References
- 38
- FWCI
- 33.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.